Health News

New drug targeting genetic weakness could become first treatment for childhood brain cancer

 9 months ago       75 Views

A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease.

The prototype treatment could also offer hope for patients with the rare and devastating 'stone man syndrome' - in which muscles and ligaments turn to bone.

Scientists at The Institute of Cancer Research, London, led research with an international team of colleagues, finding that the new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumors in mice.

Open science company M4K (Medicines for Kids) Pharma has taken on development of the ACVR1 inhibitor drugs - and clinical trials in children with brain cancer are expected to begin in 2021.

There have been no new drugs licensed to treat brain cancer in adults or children for 20 years.

The new type of drug targets the protein molecule produced by mutated versions of the ACVR1 gene found in the deadly childhood brain cancer 'diffuse intrinsic pontine glioma' (DIPG).


Author: @DailyCupofYoga

Source: news-medical.net

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.